What's New

February 7, 2011

BioMarck Pharmaceuticals Reports Phase II Study Results for COPD Inhalation Solution

September 6, 2010

BioMarck Pharmaceuticals Announces Completion of Enrollment in the BREATH 1 Study

March 6, 2009

BioMarck Pharmaceuticals Announces the Allowance of Two US Patents on Lead COPD Therapeutic

February 2, 2009

BioMarck Pharmaceuticals Awarded Grant by National Institutes for Health

January 29, 2009

BioMarck Pharmaceuticals 2009 ATS Abstract

Welcome

BioMarck Pharmaceuticals, Ltd. is a privately owned biopharmaceutical company dedicated to the discovery and development of new drugs for the treatment of pulmonary diseases and disorders associated with the over-secretion of mucus and pulmonary inflammation. In developing its lead compound, BIO-11006 Inhalation Solution, BioMarck has chosen chronic obstructive pulmonary disease (specifically chronic bronchitis) as its first target, but other diseases including asthma, and cystic fibrosis are later disease targets. BIO-11006 Inhalation Solution works by a novel dual mechanism; it inhibits both the secretion of mucus in the lungs and pulmonary inflammation. These aspects of BIO-11006 Inhalation Solution have been demonstrated in several different animal models. In addition, BioMarck has completed a full panel of preclinical safety studies, has an active IND with the FDA, has completed two BIO-11006 in Phase 1 clinical studies, and a Phase 2 study of the efficacy of BIO-11006 in COPD patients that demonstrated proof-of-concept of its novel COPD therapeutic. BioMarck licensed its technology on a worldwide exclusive basis from North Carolina State University, based on the work of Kenneth B. Adler, Ph.D., Professor of Cell Biology, and his co-workers.

Expert Opinions more expert opinions

 

Press Room

Press Releases

BioMarck Pharmaceuticals Reports Phase 2 Study Results for COPD Inhalation Solution

BioMarck Pharmaceuticals Initiates Phase 2 Clinical Study

BioMarck Pharmaceuticals Obtains FDA Agreement on its Phase 2 Clinical Trial Plans

BioMarck Secures Patent for Key Technology

BioMarck Pharmacueticals Raises $4 Million

Dr. Kenneth Adler Receives the Prestigious O. Max Gardner Award

Watch Dr. Adler's UNC TV Webcast

Dr. Kenneth Adler wins the prestigious NIH Merit Award

Abstracts

Inhibition of Myristoylated Alanine-Rich C-Kinase Substrate Protein Markedly Inhibits Ozone-Induced Airway Inflammation